Bio-Techne与Spear Bio达成战略合作 推进神经退行性疾病研究

华尔街洞察
15 Jul

Bio-Techne Corporation 宣布与 Spear Bio 达成战略合作,后者是一家专注于同质超灵敏免疫测定技术的生物技术公司。此次合作旨在加强 Spear Bio 创新的 SPEAR UltraDetect™ 免疫测定技术的全球分销,初期聚焦神经学研究市场。通过利用 Bio-Techne 广泛的分销网络,改善对 Spear Bio 技术的获取,该技术针对神经退行性疾病的关键生物标志物,包括磷酸化tau 231、磷酸化tau 217、胶质纤维酸性蛋白和神经丝轻链。这一联盟延续了 Bio-Techne 在2024年参与的 Spear Bio 4500万美元A轮融资,并突显了对推进炎症和肿瘤学等领域生物标志物检测的坚定承诺。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10